Dextech Medical AB announced the application for a phase1 study regarding OsteoDex's effect on patients with multiple myeloma that was submitted to the Medical Products Agency on June 23, 2022 has been approved and granted permission August 10, 2022. The study will include 20 patients and be conducted at 5 hospital centers in Sweden and Norway. The start of the study is expected to be third quarter of 2022 and first quarter of 2023 and is expected to be completed third quarter of 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.34 SEK | -1.36% | -11.43% | +10.43% |
26/04 | Dextech Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
15/04 | DexTech Medical Announces New Positive Results from the Myeloma Study | CI |
1st Jan change | Capi. | |
---|---|---|
+10.43% | 74.93L | |
+9.42% | 11TCr | |
+11.84% | 11TCr | |
-1.05% | 2.2TCr | |
-14.15% | 2.19TCr | |
-5.29% | 1.92TCr | |
-4.16% | 1.81TCr | |
-38.29% | 1.77TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.24TCr |
- Stock Market
- Equities
- DEX Stock
- News Dextech Medical AB
- Dextech Medical AB Announces Application Approval for Myeloma Study from Medical Products Agency